Cellular Bio Acquires Rights to Solid Tumor Immunotherapy from National Cancer Institute
October 03, 2018 at 05:48 AM EDT
Cellular Biomedicine has been granted a Patent License for a next-gen neoantigen-reactive tumor infiltrating lymphocyte (TIL) technology from the National Cancer Institute of the US. The License gives CBMG non-exclusive, sub-licensable global rights to develop, manufacture and commercialize TIL technology. Financial details were not disclosed, nor did CMBG explain why the technology is "next-gen." Headquartered in Silicon Valley, CBMG has operations in Shanghai and Beijing , where it develops immunotherapies for cancer and stem cell treatments for degenerative diseases. More details... Stock Symbol: (NSDQ: CBMG) Share this with colleagues: // //